Detail page

Knowledge Web

Person

Jessica C. Hassel (1975-)

Ärztin

Name	Jessica C. Hassel
Time	1975- (Date of birth and death)
Place	Heidelberg (Wirkungsort) Deutschland
Academic degree	Dr. med.
Profession	Ärztin (characteristic profession)
Variant	Jessica Hassel Jessica Cecile Hassel J. C. Hassel Jessica C. Morcinek (früherer Name)
Related	Klinikum Heidelberg
Further information	Diss. Medizinische Fakultät; geb. in Port of Spain, Trinidad und Tobago; Oberärztin und Zentrumskoordination Dermatologische Ambulanz und Tagesklinik im NCT, Hautklinik, Universitätsklinikum Heidelberg
Record type	Person
GND-Identifier	129790702
Record ID	129790702
Involved in show all Preferences of physicians for treatment-related toxicity vs. recurrence in melanoma (GERMELATOX-A): the doctors’ perspective Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients Preferences of physicians for treatment-related toxicity vs. recurrence in melanoma (GERMELATOX-A): the doctors’ perspective Uveamelanome Preferences of German and Swiss melanoma patients for toxicities versus melanoma recurrence during adjuvant treatment (GERMELATOX-A-trial) Liver-directed treatment is associated with improved survival and increased response to immune checkpoint blockade in metastatic uveal melanoma: results from a retrospective multicenter trial Fertilitätserhalt beim Melanom – eine große Entlastung der Betroffenen Liver-directed treatment is associated with improved survival and increased response to immune checkpoint blockade in metastatic uveal melanoma: results from a retrospective multicenter trial Preferences of German and Swiss melanoma patients for toxicities versus melanoma recurrence during adjuvant treatment (GERMELATOX-A-trial) Tolerability of BRAF and MEK Inhibitors for Metastasized Melanoma after Intra-Class Switch: A Multicenter, Retrospective Study Cytokine alterations during paraneoplastic neutrophilia and leukemoid reaction in patients with advanced melanoma Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy Long-term neurocognitive function after whole-brain radiotherapy in patients with melanoma brain metastases in the era of immunotherapy Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Re-Induction following Resistance or Toxicity Long-Term Management of Advanced Basal Cell Carcinoma: Current Challenges and Future Perspectives Real-World Therapy with Pembrolizumab : Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany Reinduction of Hedgehog Inhibitors after Checkpoint Inhibition in Advanced Basal Cell Carcinoma : A Series of 12 Patients Immune-related adverse events of COVID-19 vaccination in skin cancer patients receiving immune-checkpoint inhibitor treatment Assessment of early metabolic progression in melanoma patients under immunotherapy: an 18F-FDG PET/CT study Development and validation of a web-based patient decision aid for immunotherapy for patients with metastatic melanoma: study protocol for a multicenter randomized trial Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study Expression of potential targets for cell-based therapies on melanoma cells Factors Influencing the Adjuvant Therapy Decision: Results of a Real-World Multicenter Data Analysis of 904 Melanoma Patients Fertility preservation and management of pregnancy in melanoma patients requiring systemic therapy Immune Checkpoint Blockade for Metastatic Uveal Melanoma : Patterns of Response and Survival According to the Presence of Hepatic and Extrahepatic Metastasis Immune checkpoint blockade for metastatic uveal melanoma: patterns of response and survival according to the presence of hepatic and extrahepatic metastasis Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG) Deep abscopal response to radiotherapy and anti-PD-1 in an oligometastatic melanoma patient with unfavorable pretreatment immune signature Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients Deep abscopal response to radiotherapy and anti-PD-1 in an oligometastatic melanoma patient with unfavorable pretreatment immune signature Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG) Treatment Motivations and Expectations in Patients with Actinic Keratosis: A German-Wide Multicenter, Cross-Sectional Trial Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study Macroangiopathy is a positive predictive factor for response to immunotherapy First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study Can benign lymphoid tissue changes in 18F-FDG PET/CT predict response to immunotherapy in metastatic melanoma? COOLHAIR: a prospective randomized trial to investigate the efficacy and tolerability of scalp cooling in patients undergoing (neo)adjuvant chemotherapy for early breast cancer Longitudinal studies of the 18F-FDG kinetics after ipilimumab treatment in metastatic melanoma patients based on dynamic FDG PET/CT Rituximab as a therapeutic option for patients with advanced melanoma The role of interim 18F-FDG PET/CT in prediction of response to ipilimumab treatment in metastatic melanoma Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients Absolute number of new lesions on 18F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab Characterization of arthralgia induced by PD-1 antibody treatment in patients with metastasized cutaneous malignancies Malignes Melanom : Aktueller Stand Liquid Biopsy: Value for Melanoma Therapy? Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions Fractal and multifractal analysis of PET/CT images of metastatic melanoma before and after treatment with ipilimumab Immunotherapy of Melanoma Primary melanoma of the prostate: case report and review of the literature Randomized controlled trial to evaluate the effects of ethyl-2-cyanoacrylate on pain intensity and quality of life in head and neck cancer patients suffering from cetuximab-induced rhagades during radioimmunotherapy: the support trial Primary melanoma of the prostate: case report and review of the literature Kutane Nebenwirkungen der medikamentösen Tumortherapie mit BRAF- und MEK-Inhibitoren Randomized controlled trial to evaluate the effects of ethyl-2-cyanoacrylate on pain intensity and quality of life in head and neck cancer patients suffering from cetuximab-induced rhagades during radioimmunotherapy: the support trial Adenoviruses Using the Cancer Marker EphA2 as a Receptor In Vitro and In Vivo by Genetic Ligand Insertion into Different Capsid Scaffolds Differentiation of irradiation and cetuximab induced skin reactions in patients with locally advanced head and neck cancer undergoing radioimmunotherapy: the HICARE protocol (Head and neck cancer: ImmunoChemo and Radiotherapy with Erbitux) – a multicenter phase IV trial Treatment of Epidermal Growth Factor Receptor Antagonist-Induced Skin Rash: Results of a Survey among German Oncologists Untersuchungen zur Apoptoseregulation durch die Melanom induzierende Rezeptortyrosinkinase Xmrk Untersuchungen zur Apoptoseregulation durch die Melanom-induzierende Rezeptortyrosinkinase Xmrk

Please note

The beta version does not yet contain all functions and information of the DNB portal catalogue. If you are missing information or want to order a medium, please visit the page in the DNB portal catalogue via the following link:

Katalog der Deutschen Nationalbibliothek

Jessica C. Hassel (1975-)

Preferences of physicians for treatment-related toxicity vs. recurrence in melanoma (GERMELATOX-A): the doctors’ perspective

Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients

Preferences of physicians for treatment-related toxicity vs. recurrence in melanoma (GERMELATOX-A): the doctors’ perspective

Uveamelanome

Preferences of German and Swiss melanoma patients for toxicities versus melanoma recurrence during adjuvant treatment (GERMELATOX-A-trial)

Liver-directed treatment is associated with improved survival and increased response to immune checkpoint blockade in metastatic uveal melanoma: results from a retrospective multicenter trial

Fertilitätserhalt beim Melanom – eine große Entlastung der Betroffenen

Liver-directed treatment is associated with improved survival and increased response to immune checkpoint blockade in metastatic uveal melanoma: results from a retrospective multicenter trial

Preferences of German and Swiss melanoma patients for toxicities versus melanoma recurrence during adjuvant treatment (GERMELATOX-A-trial)

Tolerability of BRAF and MEK Inhibitors for Metastasized Melanoma after Intra-Class Switch: A Multicenter, Retrospective Study

Cytokine alterations during paraneoplastic neutrophilia and leukemoid reaction in patients with advanced melanoma

Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy

Long-term neurocognitive function after whole-brain radiotherapy in patients with melanoma brain metastases in the era of immunotherapy

Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Re-Induction following Resistance or Toxicity

Long-Term Management of Advanced Basal Cell Carcinoma: Current Challenges and Future Perspectives

Real-World Therapy with Pembrolizumab : Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany

Reinduction of Hedgehog Inhibitors after Checkpoint Inhibition in Advanced Basal Cell Carcinoma : A Series of 12 Patients

Immune-related adverse events of COVID-19 vaccination in skin cancer patients receiving immune-checkpoint inhibitor treatment

Assessment of early metabolic progression in melanoma patients under immunotherapy: an 18F-FDG PET/CT study

Development and validation of a web-based patient decision aid for immunotherapy for patients with metastatic melanoma: study protocol for a multicenter randomized trial

Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study

Expression of potential targets for cell-based therapies on melanoma cells

Factors Influencing the Adjuvant Therapy Decision: Results of a Real-World Multicenter Data Analysis of 904 Melanoma Patients

Fertility preservation and management of pregnancy in melanoma patients requiring systemic therapy

Immune Checkpoint Blockade for Metastatic Uveal Melanoma : Patterns of Response and Survival According to the Presence of Hepatic and Extrahepatic Metastasis

Immune checkpoint blockade for metastatic uveal melanoma: patterns of response and survival according to the presence of hepatic and extrahepatic metastasis

Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG)

Deep abscopal response to radiotherapy and anti-PD-1 in an oligometastatic melanoma patient with unfavorable pretreatment immune signature

Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients

Deep abscopal response to radiotherapy and anti-PD-1 in an oligometastatic melanoma patient with unfavorable pretreatment immune signature

Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG)

Treatment Motivations and Expectations in Patients with Actinic Keratosis: A German-Wide Multicenter, Cross-Sectional Trial

Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study

Macroangiopathy is a positive predictive factor for response to immunotherapy

First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis

Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study

Can benign lymphoid tissue changes in 18F-FDG PET/CT predict response to immunotherapy in metastatic melanoma?

COOLHAIR: a prospective randomized trial to investigate the efficacy and tolerability of scalp cooling in patients undergoing (neo)adjuvant chemotherapy for early breast cancer

Longitudinal studies of the 18F-FDG kinetics after ipilimumab treatment in metastatic melanoma patients based on dynamic FDG PET/CT

Rituximab as a therapeutic option for patients with advanced melanoma

The role of interim 18F-FDG PET/CT in prediction of response to ipilimumab treatment in metastatic melanoma

Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients

Absolute number of new lesions on 18F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab

Characterization of arthralgia induced by PD-1 antibody treatment in patients with metastasized cutaneous malignancies

Malignes Melanom : Aktueller Stand

Liquid Biopsy: Value for Melanoma Therapy?

Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions

Fractal and multifractal analysis of PET/CT images of metastatic melanoma before and after treatment with ipilimumab

Immunotherapy of Melanoma

Primary melanoma of the prostate: case report and review of the literature

Randomized controlled trial to evaluate the effects of ethyl-2-cyanoacrylate on pain intensity and quality of life in head and neck cancer patients suffering from cetuximab-induced rhagades during radioimmunotherapy: the support trial

Primary melanoma of the prostate: case report and review of the literature

Kutane Nebenwirkungen der medikamentösen Tumortherapie mit BRAF- und MEK-Inhibitoren

Randomized controlled trial to evaluate the effects of ethyl-2-cyanoacrylate on pain intensity and quality of life in head and neck cancer patients suffering from cetuximab-induced rhagades during radioimmunotherapy: the support trial

Adenoviruses Using the Cancer Marker EphA2 as a Receptor In Vitro and In Vivo by Genetic Ligand Insertion into Different Capsid Scaffolds

Differentiation of irradiation and cetuximab induced skin reactions in patients with locally advanced head and neck cancer undergoing radioimmunotherapy: the HICARE protocol (Head and neck cancer: ImmunoChemo and Radiotherapy with Erbitux) – a multicenter phase IV trial

Treatment of Epidermal Growth Factor Receptor Antagonist-Induced Skin Rash: Results of a Survey among German Oncologists

Untersuchungen zur Apoptoseregulation durch die Melanom induzierende Rezeptortyrosinkinase Xmrk

Untersuchungen zur Apoptoseregulation durch die Melanom-induzierende Rezeptortyrosinkinase Xmrk